Effect of Hyaluronan-enriched Medium on the Cumulative On... | NCT04697823

NCT04697823

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Oversight Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
study group	Active Comparator	Patients receiving an embryo transfer in hyaluronan-enriched transfer medium	Other: use of hyaluronan-enriched transfer medium
control group	No Intervention	Patients receiving an embryo transfer in conventional culture medium

Interventions

Name	Type	Description	Arm Group Labels	Other Names
use of hyaluronan-enriched transfer medium	Other	In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium	study group

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
number of transfers needed to reach ongoing pregnancy	The primary outcome parameter is the number of transfers needed to reach ongoing pregnancy (ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy), as a time-to-event outcome variable. Patients that do not reach pregnancy, are censored at their last transfer.	ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy

Secondary Outcomes

Measure	Description	Time Frame
number of transfers needed to reach clinical pregnancy, life birth, miscarriage, multiple pregnancy	clinical pregnancy is defined as a pregnancy with at least one intrauterine (IU) or extrauterine (EU) fetal sac at 6-7 weeks of pregnancy)	until Live birth: 9 months after ET

Eligibility Module

Contacts/Locations Module